Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:07:53.286Z.
Calculation as of: 2026-10-06T19:07:53.286Z.
Quote observation: 2026-10-06T19:01:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ee26685a5d6dda55be8f646f5bdd6a865e7c0271b97e419ee039990db4d6ed05
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$1.02M
PS Ratio
10.47
TTM Avg
20733.20
3Y Avg
20733.20
5Y Avg
20733.20
Market Cap
$1.40M
PS Ratio
21.57
TTM Avg
232.09
3Y Avg
232.09
5Y Avg
232.09
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | $1.17M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.15M | 0.04 | 0.21 | 0.18 | 0.97 |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | 10.47 | 20733.20 | 20733.20 | 20733.20 |
| NewcelX Ltd. (NCEL)vs › | $1.34M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.34M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.36M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.40M | 21.57 | 232.09 | 232.09 | 232.09 |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | 0.19 | 0.23 | 0.46 | 3.45 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q2 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-17 |
| Q3 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q4 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-09-25 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
